Sugi Predict

Sugi Predict / Targets / S100A9

S100A9

Protein S100-A9 · P06702 · S100A9 on Sugi Atlas →

1,276 patent compounds predicted against S100A9, 456 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL16235380 SCHEMBL16235380 1.00 18/20
SCHEMBL16235424 SCHEMBL16235424 1.00 18/20
SCHEMBL16235446 SCHEMBL16235446 1.00 18/20
SCHEMBL16235460 SCHEMBL16235460 1.00 18/20
SCHEMBL16235679 SCHEMBL16235679 1.00 18/20
SCHEMBL16235681 SCHEMBL16235681 0.80 18/20
SCHEMBL16235258 SCHEMBL16235258 0.77 18/20
SCHEMBL16235069 SCHEMBL16235069 0.70 18/20
SCHEMBL16235039 SCHEMBL16235039 0.67 18/20
SCHEMBL16235552 SCHEMBL16235552 0.64 18/20
SCHEMBL16235239 SCHEMBL16235239 1.00 17/20
SCHEMBL16236019 SCHEMBL16236019 1.00 17/20
SCHEMBL16235238 SCHEMBL16235238 0.83 17/20
SCHEMBL16235485 SCHEMBL16235485 0.79 17/20
SCHEMBL16235490 SCHEMBL16235490 0.78 17/20
SCHEMBL16235029 SCHEMBL16235029 0.75 17/20
SCHEMBL16235727 SCHEMBL16235727 0.73 17/20
SCHEMBL16235983 SCHEMBL16235983 0.68 17/20
SCHEMBL16235220 SCHEMBL16235220 0.67 17/20
SCHEMBL16235097 SCHEMBL16235097 0.67 17/20

Clinical trials — most relevant to S100A9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Serum Calprotectin Level in Patients With Rheumatoid Arthritis and Osteoarthritis PHASE4UNKNOWN
Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid PHASE3COMPLETED
Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics PHASE1RECRUITING
S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis nanCOMPLETED
S100A8/A9 and Innate Immunity in Liver Disease nanUNKNOWN
Neurological Prognostication of Patients in Therapeutic Hypothermia After Cardiac Arrest nanCOMPLETED
Protein S100B Versus Neutrophils/Lymphocytes Ratio in Early Prediction of Brain Injury nanCOMPLETED
Diode Laser and S100A8 in Peri-Implantitis nanCOMPLETED
Role of Calcium Binding Protein S100A12 in Diagnosis and Prognosis of Kawasaki Disease nanUNKNOWN
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life nanCOMPLETED
Evaluation of s100β, NSE and GFAP Levels in Renal Transplantation nanCOMPLETED
S100 Protein in Minor/Mild Traumatic Brain Injury nanCOMPLETED
Interventional Study for Detection of Prognosis of Blood Based Biomarkers in Intracerebral Hemorrhage nanNOT_YET_RECRUITING
GRINCH: Groningen Initiative on Reference Intervals in Children nanCOMPLETED
Urine Concentration of S100B in Extremely Premature Infants nanCOMPLETED
Predisposition to Infectious Endocarditis nanUNKNOWN
OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome nanCOMPLETED
S100B in the Care of Non-traumatic Headaches in the Emergency Department nanCOMPLETED
Diagnostic Performance of the S100B Protein in the Prognosis of Patients With Mild Head Trauma With Risk of Complications in Patients Over 65 Years Old. nanUNKNOWN
Evaluation of the Predictive Impact of Serum S100B and S100B Polymorphisms on Postoperative Cognitive Dysfunction and Delirium nanCOMPLETED
Evaluation of Serological Markers of Vitiligo Activity nanACTIVE_NOT_RECRUITING
S100β and Neuron Specific Enolase Levels in Liver Transplantation nanCOMPLETED
Soluble Forms and Ligands of RAGE in ALI/ARDS (SoLiRAGE). nanCOMPLETED
Single-center Transversal Observational Study on the Evaluation of S100B Changes in Subjects Attending the Emergency Department With Head Trauma nanRECRUITING
Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty nanCOMPLETED
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study nanCOMPLETED
The Clinical Utility of Fecal Caprotectin and Lactoferrin in Patients Undergoing Capsular Endoscopy nanUNKNOWN
Using Routine Inflammatory and Metabolic Blood Tests (Bedside Included) to Predict Brain Injury in Children After Minor Head Trauma nanNOT_YET_RECRUITING
Sepsis Associated Encephalopathy (SAE) Biomarkers nanACTIVE_NOT_RECRUITING
MD2, Cystatin C and DNA Methylation Tags as Serum Biomarkers for POCD. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a S100A9 binder may also engage these)

ProteinNameSimilarity
P31725 — 1.000 P31725 →
P50116 — 0.992 P50116 →
P50117 — 0.992 P50117 →
Q28050 — 0.987 Q28050 →
P31151 — 0.987 P31151 →
P28318 — 0.985 P28318 →
Q6S5I3 — 0.984 Q6S5I3 →
O77791 — 0.982 O77791 →
P28782 — 0.982 P28782 →
A7K6Y9 — 0.982 A7K6Y9 →
P05942 — 0.981 P05942 →
S100A8 Protein S100-A8 0.980 landscape →
Q9D2Q8 — 0.980 Q9D2Q8 →
P80310 — 0.980 P80310 →
Q14ST5 — 0.979 Q14ST5 →
P79105 — 0.978 P79105 →
Q86SG5 — 0.978 Q86SG5 →
P27004 — 0.977 P27004 →
Q8WXG8 — 0.976 Q8WXG8 →
P28783 — 0.976 P28783 →
P33763 — 0.975 P33763 →
Q3MHP3 — 0.975 Q3MHP3 →
P02632 — 0.975 P02632 →
P63084 — 0.975 P63084 →
P80511 — 0.975 P80511 →
A7K6Y8 — 0.974 A7K6Y8 →
Q5SY68 — 0.974 Q5SY68 →
P0CM55 — 0.973 P0CM55 →
P63083 — 0.973 P63083 →
Q2TBI5 — 0.973 Q2TBI5 →